A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced/Metastatic Solid Tumors
收藏DataCite Commons2026-03-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012877/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D). The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of ASP9801 as a single agent, as well as in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) checkpoint inhibitor.
提供机构：
Vivli
创建时间：
2026-03-25
